Repurposing Valsartan May Protect Against Pulmonary Hypertension

Part of paid clinical trials in Seattle, Washington.

Sponsor
University of Washington
Study ID
NCT06053580
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Pulmonary Arterial Hypertension
  • Pulmonary Vascular Disorder
  • Right Heart Failure
  • Right Ventricular Dysfunction

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Valsartan 40 mg — DRUG
    Valsartan 40mg twice daily for 24 weeks.
  • Placebo — DRUG
    Placebo twice daily for 24 weeks.

Study Details

This is a Phase 2, single-center, randomized placebo controlled trial of valsartan (an angiotensin receptor blocker) in adults with pulmonary arterial hypertension. The study will evaluate the safety and clinical efficacy of a 24-week course of valsartan.

Key Dates

Start date
Feb 28, 2024
Status verified
Apr 2026
Primary completion
Jul 1, 2027
Completion
Jul 1, 2027

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Valsartan
    Valsartan 40mg capsule taken twice daily for 24 weeks.
  • Placebo Comparator: Placebo
    Placebo capsule taken twice daily for 24 weeks.

Primary Outcome Measure

Six-minute walk distance [ Time Frame: 0 to 24 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Washington Medical CenterSeattleWashington98195
Laurie Hogl
[email protected]
2065438334
Peter J Leary, MD, PhD (PRINCIPAL_INVESTIGATOR)
Yonatan Buber, MD (SUB_INVESTIGATOR)
Sam G Rayner, MD (SUB_INVESTIGATOR)
Lia M Barros, DNP (SUB_INVESTIGATOR)

Find similar trials in Seattle, WA

By research site
University of Washington Medical Center· Seattle, WA

Related Studies